DK4185318T3 - Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme - Google Patents

Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme

Info

Publication number
DK4185318T3
DK4185318T3 DK22728724.0T DK22728724T DK4185318T3 DK 4185318 T3 DK4185318 T3 DK 4185318T3 DK 22728724 T DK22728724 T DK 22728724T DK 4185318 T3 DK4185318 T3 DK 4185318T3
Authority
DK
Denmark
Prior art keywords
prolonged
treatment
eye diseases
vegf antagonist
angiogenic eye
Prior art date
Application number
DK22728724.0T
Other languages
Danish (da)
English (en)
Inventor
Robert L Vitti
Alyson J Berliner
Karen Chu
Friedrich Asmus
Silva Leal Sergio Casimiro Da
Thomas Eissing
Kay D Rittenhouse
Original Assignee
Regeneron Pharma
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81975181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4185318(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Bayer Healthcare Llc filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK4185318T3 publication Critical patent/DK4185318T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK22728724.0T 2021-05-17 2022-05-16 Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme DK4185318T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US202263306315P 2022-02-03 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
DK4185318T3 true DK4185318T3 (da) 2025-09-29

Family

ID=81975181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22728724.0T DK4185318T3 (da) 2021-05-17 2022-05-16 Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme

Country Status (23)

Country Link
US (1) US20230302085A1 (enExample)
EP (2) EP4647125A3 (enExample)
JP (1) JP2024519629A (enExample)
KR (1) KR20240008821A (enExample)
AU (2) AU2022275786C1 (enExample)
BR (1) BR112023023002A2 (enExample)
CA (1) CA3190663A1 (enExample)
CL (3) CL2023003396A1 (enExample)
DK (1) DK4185318T3 (enExample)
ES (1) ES3041647T3 (enExample)
FI (1) FI4185318T3 (enExample)
HR (1) HRP20251282T8 (enExample)
IL (1) IL308505A (enExample)
JO (1) JOP20230283A1 (enExample)
LT (1) LT4185318T (enExample)
MX (1) MX2023013554A (enExample)
PE (1) PE20240922A1 (enExample)
PL (1) PL4185318T3 (enExample)
PT (1) PT4185318T (enExample)
RS (1) RS67369B1 (enExample)
SI (1) SI4185318T1 (enExample)
TW (1) TW202313095A (enExample)
WO (1) WO2022245739A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202400214A (zh) * 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
US20230295266A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
KR20260096819A (ko) * 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CA2866232A1 (en) 2012-05-25 2013-11-28 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015173260A1 (en) 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
IL318292A (en) 2017-12-13 2025-03-01 Regeneron Pharma Devices and methods for administering precise doses
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020345174A1 (en) * 2019-09-12 2022-03-31 Lupin Limited Modified dosing of VEGF inhibitors for ophthalmic use
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021129658A1 (zh) 2019-12-24 2021-07-01 信达生物制药(苏州)有限公司 融合蛋白在治疗年龄相关性黄斑变性中的应用
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
TW202400214A (zh) 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案

Also Published As

Publication number Publication date
EP4185318A1 (en) 2023-05-31
AU2025226774A1 (en) 2025-09-25
AU2022275786A1 (en) 2023-04-06
EP4185318B1 (en) 2025-09-03
HRP20251282T8 (hr) 2025-12-19
BR112023023002A2 (pt) 2024-01-23
TW202313095A (zh) 2023-04-01
FI4185318T3 (fi) 2025-10-13
AU2022275786B2 (en) 2025-06-05
RS67369B1 (sr) 2025-11-28
JP2024519629A (ja) 2024-05-21
US20230302085A1 (en) 2023-09-28
CL2025001269A1 (es) 2025-08-22
PE20240922A1 (es) 2024-04-30
CA3190663A1 (en) 2022-11-24
HRP20251282T1 (hr) 2025-12-05
CL2023003396A1 (es) 2024-06-07
JOP20230283A1 (ar) 2023-11-06
MX2023013554A (es) 2023-11-29
PL4185318T3 (pl) 2026-01-12
PT4185318T (pt) 2025-09-29
SI4185318T1 (sl) 2025-10-30
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
LT4185318T (lt) 2025-11-10
CL2024002972A1 (es) 2025-01-24
WO2022245739A1 (en) 2022-11-24
EP4647125A3 (en) 2026-01-28
AU2022275786A8 (en) 2023-04-20
KR20240008821A (ko) 2024-01-19
AU2022275786C1 (en) 2025-12-11
ES3041647T3 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
CY1125621T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση των διαταραχων ανωμαλης, ακουσιας κινησης
SI4185318T1 (sl) Razširjeni režimi antagonistov VEGF z visokimi odmerki za zdravljenje angiogenih očesnih bolezni
DK3716992T3 (da) Anvendelse af en VEGF-antagonist til behandling af angiogene øjenlidelser
EP4149460C0 (en) THERAPEUTIC SOLID DOSAGE FORMS
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
EP3740152A4 (en) SURGICAL PLATFORM EQUIPPED WITH ADJUSTABLE ARM SUPPORTS
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
IL291486A (en) Therapeutic conjugates
IL315347A (en) Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
IL290660A (en) Medical protein concentrates
IL292502A (en) Therapeutic methods using vadadustat
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EP4203928A4 (en) Inhalable therapeutic agents
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
EP4007553C0 (en) MIRROR THERAPY DEVICE
BR112018068960A2 (pt) formulações de enalapril